[fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”10px” padding_bottom=”10px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”” class=”” id=””][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text]Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. If you would like to learn more about our trials, please call Stacey Harrelson, RN at (843) 449-1010 ext. 268. You may also email us by clicking here.[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”20px” padding_bottom=”20px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”prostate” class=”” id=”trials”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_title size=”1″ content_align=”left” style_type=”single solid” sep_color=”” margin_top=”” margin_bottom=”” class=”” id=””]Prostate Cancer[/fusion_title][fusion_text]

Prostate Cancer – Active Surveillance

Study Name: ENACT
Description: A Randomized Study of Enzalutamide in Patients with Localized Prostate Cancer Undergoing Active Surveillance (ENACT)
Exclusion Criteria:

  • Prior radiotherapy, surgery, chemotherapy, or hormonal therapy for prostate cancer
  • Presence of metastatic disease
  • History of seizure or any condition that may predispose to seizures (e.g., prior cortical stroke or significant brain trauma) at any time in the past.
  • History of loss of consciousness or transient ischemic attack within 12 months of screening
  • Major surgery within 4 weeks prior to Randomization Visit
  • Clinically significant cardiovascular disease

Study Product: Enzalutamide
Length: 2-3 years or until disease progression

Prostate Cancer – Initiating ADT

Study Name: ATLAS
Description: A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy
Exclusion Criteria:

  • Distant metastasis
  • History of bilateral orchiectomy
  • Pelvic radiation
  • Seizure

Study Product: JNJ-56021927 (also referred to as ARN-509) and bicalutamide
Length: Until disease progression

Study Name: ARCHES

Description: A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Exclusion Criteria:

  • Subject has received any prior pharmacotherapy, radiation therapy or surgery for metastatic prostate cancer
  • Subject had a major surgery within 4 weeks prior to day 1
  • Subject received treatment with 5-α reductase inhibitors within 4 weeks prior to day 1.
  • Subject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.
  • Subject received treatment with systemic glucocorticoids greater than the equivalent of 10 mg per day of prednisone within 4 weeks prior to day 1.
  • Subject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.
  • Subject has known or suspected brain metastasis or active leptomeningeal disease.
  • Subject has a history of another invasive cancer within 3 years of screening
  • Subject has a history of seizure
  • Subject has history of loss of consciousness or transient ischemic attack within 12 months prior to day 1.
  • Subject has clinically significant cardiovascular disease
  • Subject has any concurrent disease, infection or comorbid condition that would interfere with the ability to participate in study

Study Product: Enzalutamide
Length: Until disease progression

Study Name: ADAPT
Description: Race, Bone Health and the Cardiometabolic Consequences of Androgen Deprivation Therapy for Prostate Cancer
Exclusion Criteria:

  • Receipt of ADT or any medically castrating agent at any time point prior to enrollment
  • Use of bisphosphonates, denosumab or selective estrogen receptor modulators
  • (SERMs) at any time point prior to enrollment
  • A medical history of osteoporosis or osteopenia with a planned treatment use of either bisphosphonates, SERMs or denosumab while on study*.
  • Use of a 5α-reductase inhibitor (ARI) within 6 months of enrollment*
  • Evidence of metastatic disease (positive lymph nodes are acceptable)
  • Baseline DEXA with a T-score of ≤ -2.5 at any site

Study Product: N/A
Length: 12 Months

Prostate Cancer – PSA Relapse

Study Name: EMBARK
Description: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy
Exclusion Criteria:

  • Evidence of metastatic disease
  • Prior hormone therapy (other than neoadjuvant/adjuvant therapy < 36 months in duration and > 9 months before starting study)
  • Prior cytotoxic chemotherapy, aminoglutethimide, ketoconazole, abiraterone acetate, or enzalutamide
  • Prior systemic biologic therapy (immunotherapy)
  • Other invasive cancers within 3 years prior to study enrollment
  • History of seizures
  • Clinically significant cardiovascular disease

Study Product: Enzalutamide plus leuprolide/ Enzalutamide monotherapy/ Placebo plus leuprolide.
Length: Until disease progression.

Study Name: ARAMIS
Description: A Multinational, Randomised, Double-Blind, Placebo-Controlled, Phase III Efficacy and Safety Study of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Exclusion Criteria:

  • History or presence of metastatic disease
  • Symptomatic local-regional disease requiring medical intervention
  • Prior treatments with second generation AR inhibitors, CYP17 inhibitors
  • Prior chemotherapy or immunotherapy for prostate cancer (except adjuvant/neoadjuvant treatment completed > 2 years before study enrollment)
  • Radiation therapy within 12 weeks of starting study; Severe or uncontrolled concurrent disease or infection
  • Initiation of treatment with bisphosphonate or denosumab within 12 weeks before starting study
  • Stroke
  • Myocardial infarction
  • severe/unstable angina pectoris
  • coronary/peripheral artery bypass graft
  • congestive heart failure class III or IV

Study Product: ODM-201
Length: Until disease progression.

Prostate Cancer – MO/M1 CRPC

Study Name: TRUMPET
Description: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States
Exclusion Criteria:

  • Currently enrolled in any interventional clinical trial with a non-approved investigational agent for primary disease of CRPC at study entry
  • Receiving concomitant treatment for other cancer

Study Product: N/A
Length: 5-6 years.

Prostate Cancer – M1 CRPC

Study Name: Sotio
Description: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy
Exclusion Criteria:

  • Confirmed brain and/or leptomeningeal metastases
  • Current symptomatic cord compression requiring surgery or radiation therapy
  • Prior chemotherapy for prostate cancer
  • Inability to tolerate docetaxel and prednisone
  • HIV positive; Active hepatitis B or C
  • Active syphilis
  • Evidence of bacterial, viral or fungal infection requiring systemic treatment
  • Clinically significant cardiovascular disease including:
  • symptomatic congestive heart failure
  • unstable angina pectoris, serious cardiac arrhythmia
  • uncontrolled hypertension
  • myocardial infarction or ventricular arrhythmia or stroke within a 6 month period prior to starting study
  • serious cardiac conduction system disorders, if a pacemaker is not present
  • Pleural and pericardial effusion of any grade
  • Peripheral neuropathy greater than grade 2
  • History of malignant disease (with the exception of non-melanoma skin tumors) in the preceding five years
  • Active autoimmune disease requiring treatment
  • History of severe forms of primary immune deficiencies
  • History of anaphylaxis or other serious reaction following vaccination
  • Systemic corticosteroid at doses greater than 40mg hydrocortisone daily or equivalent for any reason other than treatment of prostate cancer within the previous 6 months
  • Systemic immunosuppressive therapy for any reason
  • Treatment with immunotherapy against prostate cancer within 6 months of starting study
  • Treatment with radiopharmaceutical within 8 weeks prior to starting study
  • Participation in a clinical trial using immunological experimental therapy (eg, monoclonal antibodies, cytokines or active cellular immunotherapies)0 within 6 months prior to starting study.

Study Product: DCVAC/PCa, active cellular immunotherapy containing autologous dendritic cells (DC) activated by transient exposure to killed prostate cancer cells ex-vivo.
Length: Until disease progression.

Study Name: Innocrin 001/003
Description: A Single-arm, Phase 2 Study to Evaluate the Safety and Efficacy of VT-464 in Patients with Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.
Exclusion Criteria:

  • Prior cytotoxic chemotherapy for prostate cancer
  • Patients who require
  • Patients who require pharmacological or replacement doses of systemic corticosteroids or who have received systemic corticosteroids within 30 days of starting study
  • CNS metastases from prostate cancer
  • History of adrenal insufficiency
  • History within the last 3 years of another invasive malignancy
  • History of clinically significant cardiac arrhythmias
  • Patients who have started or changed bisphosphonates within 3 months of starting study
  • Known active HIV, Hepatitis B, or Hepatitis C infections
  • Congestive heart failure
  • Unstable angina
  • Recent myocardial infarction
  • Acute coronary syndrome or stroke
  • Hypertension requiring more than 2 medications for adequate control
  • Diabetes mellitus with more than 2 episodes of ketoacidosis in the preceding 12 months

Study Product: VT-464
Length: Until disease progression.

Study Name: Lilly GU 115
Description: A Double-Blinded, Placebo-Controlled, Randomized Phase II Study of Enzalutamide With or Without the PI3 Kinase/mTOR Inhibitor LY3023414 in Men with Metastatic Castration Resistant Prostate Cancer
Exclusion Criteria:

  • Prior cytotoxic chemotherapy, immunotherapy, a P13K/AKT/mTOR agent, or RA 223dichloride for treatment of CRPC.
  • Prior enzalutamide treatment
  • Pathological finding consistent with small cell carcinoma of prostate
  • Prior systemic treatment with an azole drug
  • Known brain metastasis
  • History of seizure or condition that may predispose to seizure
  • Uncontrolled hypertension
  • Have serious pre-existing medical conditions
  • Have insulin-dependent diabetes mellitus
  • Presence of active gastrointestinal disease
  • Clinically significant electrolyte imbalance
  • Have an active, known fungal, bacterial, and/or known viral infection
  • Psychological, familial, sociological, or geographical conditions that do not permit compliance

Study Product: LY3023414 with enzalutamide
Length: Until disease progression.

Study Name: Janssen Parp Positive/Negative
Description: A Safety and Pharmacokinetics Study of Niraparib plus Apalutamide in Men with Metastatic Castration-Resistant Prostate Cancer
Exclusion Criteria:

  • Brain metastases
  • Prior treatment with PARP inhibitor
  • Known history or diagnosis of myelodysplastic syndrome
  • Known symptomatic or impending cord compression
  • History of seizure

Study Product: PCR1001
Length: Treatment continues until disease progression, unacceptable toxicity, death, or sponsor termination of the study.

Study Name: Janssen Parp Positive
Description: A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration – Resistant Prostate Cancer and DNA-Repair Anomalies
Exclusion Criteria:

  • Prior treatment with PARP inhibitor
  • Known history or diagnosis of myelodysplastic syndrome
  • Known symptomatic or impending cord compression
  • Known disorder affecting gastrointestinal absorption

Study Product: PCR2001
Length: Up to 22 months

Study Name: Merck
Description: Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
Exclusion Criteria:

  • Has had a prior anticancer mAb within 4 weeks prior to first dose of trial treatment
  • Currently participating in and receiving study therapy
  • Has a diagnosis of immunodeficiency or receiving systemic steroid therapy within 7 days prior to treatment
  • Prior radium treatment

Study Product: 365-03
Length: Up to 3.5 years

Study Name: AstraZeneca
Description: A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)
Exclusion Criteria:

  • Participation in another study with investigational product during last 30 days before randomization
  • Any previous PARP inhibitor treatment
  • Previous treatment with DNA-damaging chemotherapy

Study Product: D081DC00007
Length: Treatment continues until disease progression or death

Study Name: Genentech CO39385
Description: A Phase III, Multicenter, Randomized Study of Atezolizumab (ANTI – PD-L1 Antibody) in Combination with Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of, Ineligibility for, or Refusal of a Taxane Regimen
Exclusion Criteria:

  • Chemotherapy within 3 weeks
  • Treatment with abiraterone within 2 weeks
  • Malignancies other than mCRPC within 5 years prior to study treatment initiation
  • Significant cardiovascular disease

Study Product: CO39385
Length: Treatment continues until disease progression or death

Study Name: Genentech CO39303

Description: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer
Exclusion Criteria:

  • Inability or unwillingness to swallow pills
  • Malabsorption syndrome
  • Liver disease
  • Treatment with chemotherapy for treatment of CRPC
  • Use of opiate analgesics for cancer-related pain

Study Product: CO39303
Length: Up to 65 months

Prostate Cancer – Initiating ADT (Low & High Volume Disease)

Study Name: Arasens
Description: A randomized, double–blind, placebo–controlled Phase III study of ODM–201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone–sensitive prostate cancer
Exclusion Criteria:

  • Prior treatment with LHRH agonist/antagonists 12 weeks prior to randomization, Enzalutamide, ARN-509, ODM-201, AR inhibitors, Chemotherapy or immunotherapy, radiotherapy.
  • Known hypersensitivity to any study drugs
  • Contraindication to CT and MRI contrast
  • Stroke, myocardial infarction, severe angina pectoris, congestive heart failure 6 months prior to randomization
  • Uncontrolled hypertension
  • Prior malignancy
  • Gastrointestinal disorder or procedure
  • Active viral hepatitis
  • Inability to swallow oral medications

Study Product: BAY 1841788 / 17777
Length: 70 months

Study Name: Hero
Description: A Multinational Phase 3, Randomized, Open-label, Parallelgroup Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
Exclusion Criteria:

  • Likely to require chemotherapy or surgical therapy within 2 months of initiating ADT
  • Previously received GnRH analog for more than 12 months
  • Previous treatment with taxane-based regiment
  • Metastases to brain
  • Life expectancy less than 5 years
  • Scheduled for major surgery
  • Surgical castration
  • Abnormal lab values that suggest underlying disease
  • Uncontrolled diabetes
  • HIV

Study Product: (MVT-601-3201)
Length: 48 weeks

Prostate Cancer – PSA Relapse

Study Name: Panacea
Description: Phase I, Open-Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients
Exclusion Criteria:

  • PSA doubling time of less than 3 months
  • Prior major surgery or radiation therapy within 4 weeks of enrollment
  • Receipt of any blood product within 1 month of enrollment

Study Product: PAN0216
Length: 14 weeks

 [/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text][/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”20px” padding_bottom=”20px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”” class=”” id=””][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_title size=”1″ content_align=”left” style_type=”single solid” sep_color=”” margin_top=”” margin_bottom=”” class=”” id=””]Bladder Cancer[/fusion_title][fusion_text]

Study Name: Incyte
Description: A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations
Exclusion Criteria:

  • Treatment with other investigational study drug
  • Untreated brain or central nervous system metastases or brain/CNS metastases that have progressed
  • Known additional malignancy that is progressing or requires active treatment
  • History of human immunodeficiency virus
  • Evidence of hepatitis B or hepatitis C virus
  • History of uncontrolled cardiac disease
  • Undergone major surgical procedure within 28 days of Cycle 1 Day 1

Study Product: INCB054828/Incyte
Length: Until disease progression

Study Name: Genomic Health
Description: Clinical Validation of a Urine-Based Assay With Genomic and Epigenomic Markers for Predicting Recurrence During Surveillance for Non-Muscle Invasive Bladder Cancer
Exclusion Criteria:

  • Younger than 18 years
  • Prior cystectomy or prior diagnosis of muscle invasive disease
  • Unable to provide at least 45 ml of voided urine

Study Product: N/A
Length: 1 year

Study Name: FKD
Description: A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC).
Exclusion Criteria:

  • Current of previous evidence of muscle invasive metastatic disease
  • Current systemic therapy for bladder cancer
  • Current or prior pelvic external beam radiotherapy within 5 years
  • Prior adenovirus-based drug treatment
  • UTO or bacterial cystitis

Study Product: rAd-IFN-CS-003
Length: Up to 4 years

Study Name: Cellay
Description: A clinical prospective non-interventional study to validate the VesicaDx® test to detect recurrence of the disease in patients previously diagnosed with bladder cancer being monitored for recurrence.
Exclusion Criteria:

  • Less than 18 years of age
  • Non-Muscle invasive bladder cancer greater than 6 months from time of enrollment
  • Upper tract TCC (Transitional Cell Cancer)
  • Previously diagnosed and treated malignancy
  • Cystectomy prior to enrolling

Study Product: N/A
Length: Up to 2 years

Study Name: University of Wisconsin
Description: Phase II Clinical Chemoprevention Trial of Weekly Erlotinib before Bladder Cancer Surgery
Exclusion Criteria:

  • Bladder tumor treatment other than intravesical therapy
  • Any chemotherapy and/or radiation therapy received less than 3 months of study entry
  • Immunotherapy received less than 6 months of study entry

Study Product: UWI2013-01-02
Length: 3 years[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text][/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”20px” padding_bottom=”20px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”” class=”” id=””][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_title size=”1″ content_align=”left” style_type=”single solid” sep_color=”” margin_top=”” margin_bottom=”” class=”” id=””]BPH[/fusion_title][fusion_text]

Study Name: MediTate
Description: A Phase II study, randomized, controlled, efficacy assessor blinded, multicenter, international prospective study to assess the safety and effectiveness of Medi-Tate i-Temporary Implantable Nitinol Device (iTIND) in subjects with symptomatic Benign Prostatic Hyperplasia (BPH)
Exclusion Criteria:

  • Cardiac arrhythmias
  • Compromised renal function
  • Confirmed or suspected bladder cancer
  • Recent cystolithiasis or hematuria
  • Active urinary tract infection
  • Enrolled in another treatment trial
  • Previous prostate surgery, balloon dilatation, stent implantation, laser prostatectomy, hyperthermia, or any other invasive treatment to the prostate

Study Product: iTIND (i-TEMPORARY IMPLANTABLE NITINOL DEVICE)
Length: Approx. 12 months[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text][/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”20px” padding_bottom=”20px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”” class=”” id=””][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_title size=”1″ content_align=”left” style_type=”single solid” sep_color=”” margin_top=”” margin_bottom=”” class=”” id=””]Urinary Incontinence for MS or SCI[/fusion_title][fusion_text]

No current studies. Please check back soon.

[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container hundred_percent=”yes” overflow=”visible”][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text][/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”20px” padding_bottom=”20px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”” class=”” id=””][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_title size=”1″ content_align=”left” style_type=”single solid” sep_color=”” margin_top=”” margin_bottom=”” class=”” id=””]Other[/fusion_title][fusion_text]

Renal Cancer
Study Name: Genentech WO39210
Description: A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atexolizumab (Anti – PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
Exclusion Criteria:

  • Malignancies other than Renal Cell Carcinoma within 5 years prior to beginning study
  • Administration of a lice, attenuated vaccine 4 weeks before beginning study
  • Treatment with systemic immunostimulatory agents within 4-6 weeks

Study Product: WO39210
Study Length: Treatment continues until disease progression or death[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container][fusion_builder_container background_color=”” background_image=”” background_parallax=”none” enable_mobile=”no” parallax_speed=”0.3″ background_repeat=”no-repeat” background_position=”left top” video_url=”” video_aspect_ratio=”16:9″ video_webm=”” video_mp4=”” video_ogv=”” video_preview_image=”” overlay_color=”” overlay_opacity=”0.5″ video_mute=”yes” video_loop=”yes” fade=”no” border_size=”0px” border_color=”” border_style=”solid” padding_top=”20px” padding_bottom=”20px” padding_left=”0px” padding_right=”0px” hundred_percent=”no” equal_height_columns=”no” hide_on_mobile=”no” menu_anchor=”form” class=”” id=””][fusion_builder_row][fusion_builder_column type=”1_1″ background_position=”left top” background_color=”” border_size=”” border_color=”” border_style=”solid” spacing=”yes” background_image=”” background_repeat=”no-repeat” padding=”” margin_top=”0px” margin_bottom=”0px” class=”” id=”” animation_type=”” animation_speed=”0.3″ animation_direction=”left” hide_on_mobile=”no” center_content=”no” min_height=”none”][fusion_text]Please fill in the form below to email us to learn more about our trials:[/fusion_text][/fusion_builder_column][fusion_builder_column type=”1_1″ last=”yes” spacing=”yes” center_content=”no” hide_on_mobile=”no” background_color=”” background_image=”” background_repeat=”no-repeat” background_position=”left top” hover_type=”none” link=”” border_position=”all” border_size=”0px” border_color=”” border_style=”” padding=”” margin_top=”” margin_bottom=”” animation_type=”” animation_direction=”” animation_speed=”0.1″ animation_offset=”” class=”” id=””][fusion_text]

[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]